Apple vs. AliveCor: Federal Circuit Dismisses Heart Rate Patent Appeal in Record 41 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Apple, Inc. v. AliveCor, Inc. |
| Case Number | 25-1820 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District of Columbia circuit region |
| Duration | May 30, 2025 – July 10, 2025 41 days |
| Outcome | Appeal Dismissed – No Damages |
| Patents at Issue | |
| Accused Products | Seamlessly embedded heart rate monitor technology |
Case Overview
The Parties
⚖️ Plaintiff
Global technology leader known for its Apple Watch platform, a dominant force in consumer health wearables, including heart rate and ECG monitoring.
🛡️ Defendant
Specialized medical-grade cardiac monitoring company, known for its KardiaMobile ECG devices and AI-powered heart rhythm analysis, holding a substantial IP portfolio.
The Patent at Issue
This case centered on U.S. Patent No. US10076257B2, covering a foundational technology in the smartwatch and wearable ECG space:
- • US10076257B2 — Methods and systems for seamlessly embedding heart rate monitoring capabilities within a wearable device.
Developing a wearable health product?
Check if your device design might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
The Federal Circuit **dismissed the appeal** in Case No. 25-1820 on July 10, 2025, just 41 days after filing. This rapid dismissal was procedural in nature, meaning the court did not issue a substantive opinion on the merits of the patent’s validity or infringement claims. No damages were awarded or disclosed, and no injunctive relief was referenced.
Key Legal Issues
The verdict cause was “Patentability,” with the action classified as an “Invalidity/Cancellation Action.” This indicates the central legal dispute concerned whether U.S. Patent No. US10076257B2 met the statutory requirements for patentability. The dismissal, without a merits ruling, means the Federal Circuit did not establish binding precedent on heart rate monitor patent validity or the specific claim constructions at issue. This preserves uncertainty around the patent’s legal status.
Drafting patents for wearable tech?
Learn from these cases. Use AI to draft stronger claims that can withstand invalidity challenges.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This swift dismissal highlights unique IP risks in wearable health tech. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in wearable health tech patents
- Understand PTAB appeal strategies
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Seamlessly embedded heart rate monitors
Unresolved Validity
US10076257B2 status after dismissal
Strategy Focus
PTAB and appellate strategy critical
✅ Key Takeaways
For Patent Attorneys & Litigators
The 41-day dismissal timeline signals a likely procedural or negotiated resolution—review the dismissal order for strategic intelligence.
Search related case law →No merits ruling means no new Federal Circuit precedent on embedded heart rate monitor patentability.
Explore precedents →For R&D Leaders
Conduct updated FTO analysis on embedded biometric monitoring features before product launch.
Start FTO analysis for my product →The unresolved patent landscape in wearable ECG technology creates both risk and opportunity for design-around innovation.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.